iRhythm Holdings, Inc. (IRTC)
| Market Cap | 3.03B -47.8% |
| Revenue (ttm) | 854.04M +21.6% |
| Net Income | -38.59M |
| EPS | -1.18 |
| Shares Out | 33.62M |
| PE Ratio | n/a |
| Forward PE | 95.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,667,138 |
| Open | 110.36 |
| Previous Close | 130.19 |
| Day's Range | 86.30 - 112.95 |
| 52-Week Range | 86.30 - 192.47 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 166.13 (+84.14%) |
| Earnings Date | Nov 5, 2026 |
About IRTC
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that ... [Read more]
Financial Performance
In 2025, iRhythm Holdings's revenue was $747.14 million, an increase of 26.24% compared to the previous year's $591.84 million. Losses were -$44.55 million, -60.67% less than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for IRTC stock is "Strong Buy." The 12-month stock price target is $166.13, which is an increase of 84.14% from the latest price.
News
IRTC Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into iRhythm Technologies, Inc. (IRTC)
A revenue shortfall against Wall Street consensus, flat Zio AT sales, and the Zio MCT FDA submission has now slipped into 2027. SueWallSt notifies investors of a pending investigation into potential s...
iRhythm price target lowered to $140 from $168 at Truist
Truist lowered the firm’s price target on iRhythm (IRTC) to $140 from $168 and keeps a Buy rating on the shares. The firm braced for a messy Q3 and guidance…
iRhythm Holdings to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and preve...
iRhythm price target lowered to $150 from $180 at BofA
BofA lowered the firm’s price target on iRhythm (IRTC) to $150 from $180 and keeps a Buy rating on the shares after the firm updated its model for Q3 results…
iRhythm price target lowered to $170 from $185 at BTIG
BTIG lowered the firm’s price target on iRhythm (IRTC) to $170 from $185 and keeps a Buy rating on the shares after its Q3 results. The negative surprise in the…
iRhythm price target lowered to $145 from $175 at JPMorgan
JPMorgan lowered the firm’s price target on iRhythm (IRTC) to $145 from $175 and keeps an Overweight rating on the shares.
iRhythm price target raised to $206 from $196 at Canaccord
Canaccord analyst William Plovanic raised the firm’s price target on iRhythm (IRTC) to $206 from $196 and keeps a Buy rating on the shares. The firm updated its model following…
iRhythm downgraded to Neutral from Buy at Citi
Citi analyst Joanne Wuensch downgraded iRhythm (IRTC) to Neutral from Buy with a price target of $124, down from $157, following the Q3 report. The company’s increased 2026 revenue outlook…
iRhythm price target lowered to $150 from $160 at Piper Sandler
Piper Sandler analyst Adam Maeder lowered the firm’s price target on iRhythm (IRTC) to $150 from $160 and keeps an Overweight rating on the shares. The firm notes the company…
iRhythm sees FY26 revenue $890M-$895M, consensus $890.08M
For the full year 2026, iRhythm (IRTC) expects revenue between $890 million and $895 million, which includes approximately $16 million of expected VitalConnect revenue contribution from the October 5,...
iRhythm Holdings Earnings Call Transcript: Q3 2026
Q3 revenue rose 14.9% YoY, with record adjusted EBITDA margin of 23.1%; Zio monitor growth offset flat Zio AT. VitalConnect expands MCT coverage, while integration delays and the Zio MCT filing shift shape the near-term outlook.
iRhythm Holdings Earnings release: Q3 2026
iRhythm Holdings released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
iRhythm Holdings Slides: Q3 2026
iRhythm Holdings has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
iRhythm Holdings Quarterly report: Q3 2026
iRhythm Holdings has published its Q3 2026 quarterly earnings report on November 5, 2026.
iRhythm Holdings Announces Third Quarter 2026 Financial Results
SAN FRANCISCO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and preve...
iRhythm initiated with an Overweight at Piper Sandler
Piper Sandler analyst Adam Maeder initiated coverage of iRhythm (IRTC) with an Overweight rating and $160 price target The shares are down year-to-date due to a combination of factors, including…
iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026
SAN FRANCISCO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent dis...
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
iRhythm price target lowered to $150 from $168 at Wells Fargo
Wells Fargo lowered the firm’s price target on iRhythm (IRTC) to $150 from $168 and keeps an Overweight rating on the shares. The firm is updating its IRTC model following…
iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. ("VitalConnect"), a...
iRhythm provides update on cybersecurity incident previously disclosed in June
“iRhythm (IRTC) provided an update regarding the cybersecurity incident previously disclosed in June, 2026. Following completion of the forensic investigation and subsequent review to determine the na...
iRhythm Provides Update on Cybersecurity Incident Previously Disclosed in June 2026
Following completion of the forensic investigation, company begins notifying impacted individuals Following completion of the forensic investigation, company begins notifying impacted individuals
iRhythm Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference
The acquisition of VitalConnect expands the product portfolio to fully address the MCT market, leveraging differentiated technology and a larger sales force for nationwide growth. Ambitions include reaching 30%-40% MCT market share, maintaining strong EBITDA margins, and driving innovation through EHR integration and multi-vitals capabilities.